JP7014449B2 - 神経障害を処置するための間葉系細胞由来エキソソーム - Google Patents

神経障害を処置するための間葉系細胞由来エキソソーム Download PDF

Info

Publication number
JP7014449B2
JP7014449B2 JP2019508178A JP2019508178A JP7014449B2 JP 7014449 B2 JP7014449 B2 JP 7014449B2 JP 2019508178 A JP2019508178 A JP 2019508178A JP 2019508178 A JP2019508178 A JP 2019508178A JP 7014449 B2 JP7014449 B2 JP 7014449B2
Authority
JP
Japan
Prior art keywords
msc
mice
particles
btbr
saline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019508178A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019524824A5 (cg-RX-API-DMAC7.html
JP2019524824A (ja
Inventor
オフェン，ダニエル
ペレツ，ニシム
Original Assignee
ラモット アット テル アビブ ユニバーシティ， リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ラモット アット テル アビブ ユニバーシティ， リミテッド filed Critical ラモット アット テル アビブ ユニバーシティ， リミテッド
Publication of JP2019524824A publication Critical patent/JP2019524824A/ja
Publication of JP2019524824A5 publication Critical patent/JP2019524824A5/ja
Application granted granted Critical
Publication of JP7014449B2 publication Critical patent/JP7014449B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2019508178A 2016-08-14 2017-08-14 神経障害を処置するための間葉系細胞由来エキソソーム Active JP7014449B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662374852P 2016-08-14 2016-08-14
US62/374,852 2016-08-14
PCT/IL2017/050899 WO2018033911A1 (en) 2016-08-14 2017-08-14 Mesenchymal cell-derived exosomes to treat neurological disorders

Publications (3)

Publication Number Publication Date
JP2019524824A JP2019524824A (ja) 2019-09-05
JP2019524824A5 JP2019524824A5 (cg-RX-API-DMAC7.html) 2021-12-16
JP7014449B2 true JP7014449B2 (ja) 2022-02-01

Family

ID=61196484

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019508178A Active JP7014449B2 (ja) 2016-08-14 2017-08-14 神経障害を処置するための間葉系細胞由来エキソソーム

Country Status (10)

Country Link
US (2) US11129852B2 (cg-RX-API-DMAC7.html)
EP (1) EP3496730B1 (cg-RX-API-DMAC7.html)
JP (1) JP7014449B2 (cg-RX-API-DMAC7.html)
CN (1) CN109843305B (cg-RX-API-DMAC7.html)
AU (1) AU2017311684B2 (cg-RX-API-DMAC7.html)
ES (1) ES2925527T3 (cg-RX-API-DMAC7.html)
IL (1) IL264825B (cg-RX-API-DMAC7.html)
PL (1) PL3496730T3 (cg-RX-API-DMAC7.html)
SG (1) SG11201901272WA (cg-RX-API-DMAC7.html)
WO (1) WO2018033911A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11648260B2 (en) 2018-03-29 2023-05-16 Technion Research And Development Foundation Limitted Vesicles comprising a PTEN inhibitor and uses of same
CA3112505C (en) * 2018-09-20 2023-06-20 Citospin, S.L. Method for obtaining an enriched population of functional mesenchymal stem cells, cells obtained thereof and compositions comprising the same
EP3990625A4 (en) 2019-06-26 2023-07-19 Technion Research & Development Foundation Limited PRODUCTION OF EXTRACELLULAR VESICLES FROM STEM CELLS
JP6830286B1 (ja) 2020-06-26 2021-02-17 デクソンファーマシューティカルズ株式会社 精巣機能改善剤および精巣機能改善方法
US20230210910A1 (en) 2020-07-17 2023-07-06 Dexon Pharmaceuticals Inc. Method for preventing infection of a healthy person or a healthy animal with a virus that uses ace2 as a receptor, binding inhibitor and medical device
EP4212163A4 (en) 2020-09-08 2024-09-18 Dexon Pharmaceuticals Inc. CYTOKINE STORM INHIBITOR, METHOD FOR USING CYTOKINE STORM INHIBITOR, AND METHOD FOR SCREENING CYTOKINE INHIBITOR
JP6974892B1 (ja) 2021-05-27 2021-12-01 デクソンファーマシューティカルズ株式会社 癌悪液質の改善剤および癌悪液質の改善方法
JP7492757B2 (ja) 2022-03-22 2024-05-30 Ｄｅｘｏｎファーマシューティカルズ株式会社 遺伝子の発現制御剤、アルツハイマー病の予防薬または治療薬および認知症の改善方法
US20250136992A1 (en) 2022-05-15 2025-05-01 Nurexone Biologic Ltd. Anti-pten rna interference oligonucleotides and uses thereof
CN115006427A (zh) * 2022-05-31 2022-09-06 尧舜泽生物医药(南京)有限公司 骨髓间充质干细胞外泌体在治疗帕金森病中的应用
EP4541359A1 (en) 2022-06-20 2025-04-23 Dexon Pharmaceuticals Inc. Ptx3 expression control agent, prophylactic drug or therapeutic drug for vasculitis or hardening of skin associated with rheumatoid arthritis, autoimmune disease, method for improving vasculitis or hardening of skin associated with rheumatoid arthritis, autoimmune disease
WO2023248844A1 (ja) 2022-06-20 2023-12-28 Ｄｅｘｏｎファーマシューティカルズ株式会社 Ｈｍｇｂ１の発現制御剤；急性肺損傷、急性呼吸窮迫症候群または敗血症の予防薬または治療薬、あるいはそれらの改善方法
CN120078807B (zh) * 2025-02-08 2026-03-31 广东省人民医院 改善卵巢功能的MSC-sEVs药物及其制备方法和应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110014251A1 (en) 2008-01-04 2011-01-20 Lydac Neuroscience Limited Microvesicles
JP2011219432A (ja) 2010-04-13 2011-11-04 Nagoya Univ 歯髄幹細胞を用いた神経疾患治療用組成物
JP2012508733A (ja) 2008-11-14 2012-04-12 メディポスト カンパニー リミテッド 間葉幹細胞またはその培養液を含む神経疾患の予防または治療用の組成物
WO2012156968A2 (en) 2011-05-19 2012-11-22 Ariel - University Research And Development Company, Ltd. Use of mesenchymal stem cells for the improvement of affective and cognitive function
JP2016065106A (ja) 2010-03-26 2016-04-28 国立大学法人名古屋大学 損傷部治療用組成物の製造方法
WO2016149358A1 (en) 2015-03-16 2016-09-22 Duncan Ross Method of treatment comprising membrane-enclosed vesicle

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US20060188496A1 (en) * 2005-02-23 2006-08-24 Hanne Bentz Intranasal administration of active agents to the central nervous system
WO2008036374A2 (en) * 2006-09-21 2008-03-27 Medistem Laboratories, Inc. Allogeneic stem cell transplants in non-conditioned recipients
EP2254586B1 (en) 2008-02-22 2015-04-08 Agency For Science, Technology And Research (A*star) Mesenchymal stem cell particles
CN102596177B (zh) * 2009-07-01 2014-05-28 阿昂梅迪克斯公司 来源于有核哺乳动物细胞的微囊泡及其应用
GB201011589D0 (en) 2010-07-09 2010-08-25 Reneuron Ltd Therapeutic cells
WO2012020308A2 (en) * 2010-08-13 2012-02-16 The University Court Of The University Of Glasgow Cellular and molecular therapies
WO2012068170A2 (en) * 2010-11-15 2012-05-24 Jau-Nan Lee Generation of neural stem cells from human trophoblast stem cells
WO2013124817A2 (en) * 2012-02-22 2013-08-29 Brainstem Biotec Ltd. MicroRNAS FOR THE GENERATION OF ASTROCYTES
EP2833893B1 (en) 2012-04-03 2018-08-29 Reneuron Limited Stem cell microparticles
WO2013186735A2 (en) 2012-06-14 2013-12-19 Bar-Ilan Research And Development Company Ltd. Photothermal detection
WO2015038075A1 (en) * 2013-09-16 2015-03-19 Agency For Science, Technology And Research Method

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110014251A1 (en) 2008-01-04 2011-01-20 Lydac Neuroscience Limited Microvesicles
JP2012508733A (ja) 2008-11-14 2012-04-12 メディポスト カンパニー リミテッド 間葉幹細胞またはその培養液を含む神経疾患の予防または治療用の組成物
JP2016065106A (ja) 2010-03-26 2016-04-28 国立大学法人名古屋大学 損傷部治療用組成物の製造方法
JP2011219432A (ja) 2010-04-13 2011-11-04 Nagoya Univ 歯髄幹細胞を用いた神経疾患治療用組成物
WO2012156968A2 (en) 2011-05-19 2012-11-22 Ariel - University Research And Development Company, Ltd. Use of mesenchymal stem cells for the improvement of affective and cognitive function
WO2016149358A1 (en) 2015-03-16 2016-09-22 Duncan Ross Method of treatment comprising membrane-enclosed vesicle

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Autism Research，2015年08月10日，(2016) Vol. 9，pp. 17-32
Journal of Cerebral Blood Flow & Metabolism，Vol. 33，2013年，pp. 1711-1715
STEM CELLS TRANSLATIONAL MEDICINE，2015年，Vol. 4，pp. 1131-1143

Also Published As

Publication number Publication date
EP3496730A1 (en) 2019-06-19
EP3496730B1 (en) 2022-05-25
AU2017311684A2 (en) 2019-03-28
AU2017311684B2 (en) 2023-05-04
SG11201901272WA (en) 2019-03-28
AU2017311684A1 (en) 2019-03-07
JP2019524824A (ja) 2019-09-05
IL264825A (cg-RX-API-DMAC7.html) 2019-04-30
EP3496730A4 (en) 2020-05-06
CN109843305B (zh) 2023-03-10
US20210361717A1 (en) 2021-11-25
ES2925527T3 (es) 2022-10-18
CN109843305A (zh) 2019-06-04
US20190209621A1 (en) 2019-07-11
WO2018033911A1 (en) 2018-02-22
US11129852B2 (en) 2021-09-28
PL3496730T3 (pl) 2022-09-26
CA3033951A1 (en) 2018-02-22
IL264825B (en) 2022-08-01

Similar Documents

Publication Publication Date Title
JP7014449B2 (ja) 神経障害を処置するための間葉系細胞由来エキソソーム
Guo et al. Intranasal delivery of mesenchymal stem cell derived exosomes loaded with phosphatase and tensin homolog siRNA repairs complete spinal cord injury
He et al. miR-100a-5p-enriched exosomes derived from mesenchymal stem cells enhance the anti-oxidant effect in a Parkinson’s disease model via regulation of Nox4/ROS/Nrf2 signaling
Tajiri et al. Intravenous transplants of human adipose-derived stem cell protect the brain from traumatic brain injury-induced neurodegeneration and motor and cognitive impairments: cell graft biodistribution and soluble factors in young and aged rats
Chang et al. Hypoxic preconditioning enhances the therapeutic potential of the secretome from cultured human mesenchymal stem cells in experimental traumatic brain injury
Cao et al. Promoting Alzheimer’s disease research and therapy with stem cell technology
Liang et al. Mesenchymal stem cell-derived exosomes for treatment of autism spectrum disorder
Barreiro et al. Pivotal role for skin transendothelial radio-resistant anti-inflammatory macrophages in tissue repair
Mesentier-Louro et al. Bone Marrow‐Derived Cells as a Therapeutic Approach to Optic Nerve Diseases
JP2017526723A (ja) 移植片対宿主病（ｇｖｈｄ）または表皮水疱症（ｅｂ）のエキソソームによる治療方法
Min et al. BDNF-enriched small extracellular vesicles protect against noise-induced hearing loss in mice
JP2018511599A (ja) 細胞増殖の刺激のための方法及び組成物、ならびにｆｇｆ２アイソフォームの生物学的に活性な混合物の提供
US20080075698A1 (en) Brain-Localizing Bone Marrow Progenitor cells
ITUB20159750A1 (it) Metodo per la promozione ed il miglioramento delle proprieta? del tessuto adiposo, tessuto e cellule ottenute tramite detto metodo
CN116077531A (zh) 外泌体在制备脑卒中治疗用产品中的用途
JP7618191B2 (ja) 臓器線維症の予防または治療剤
CA3033951C (en) Mesenchymal cell-derived exosomes to treat neurological disorders
KR20150091519A (ko) 다계열 분화능 세포 생성 방법
CN115554316B (zh) SKP-SC-EVs在制备治疗帕金森病的产品中的应用
Bang et al. Mesenchymal Stem Cell-Extracellular Vesicle Therapy in Patients with Stroke
RU2790031C2 (ru) Способ лечения аллергического заболевания дыхательных путей (AAD)/астмы
Losurdo A new hope for alzheimer’s disease from preconditioned bone marrow mesenchymal stem cell-derived extracellular vesicles: Analysis of the Immunomodulatory effects
Maxan Mutant protein spread in Huntington's disease and its implications for other neurodegenerative disorders of the CNS
Liu Stem cells and iPSCs in neural chronic degenerative disease
JP2023155687A (ja) 微小粒子、うつ病の予防薬または治療薬およびうつ病の改善方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190417

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200717

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210622

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210910

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211027

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20211027

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211221

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220113

R150 Certificate of patent or registration of utility model

Ref document number: 7014449

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250